top of page
Search

Onco-Summaries: Daily Oncology Updates at a Glance


20/04/2026










Arcus halts Lung Cancer Trial With Gilead After Futility Analysis (Ref)


Arcus Biosciences has halted its Phase 3 lung cancer trial with Gilead Sciences, citing futility after a pre-planned analysis showed the study was unlikely to yield positive results. A related Phase 2 study was also ended


  • The decision followed recommendations from the Independent Data Monitoring Committee, which reviewed trial data. The futility analysis did not assess safety, but no new safety concerns were identified in ongoing reviews. 


  • Impact on Gilead Partnership: Under the 2020 agreement, Gilead’s option rights to certain early pipeline programs will expire in July, as the company chose not to make the continuation payment. Gilead retains only its existing time-limited options

















FDA granted Fast Track designation for Lunresertib + Zedoresertib in Platinum-Resistant Ovarian Cancer (Ref)


The FDA granted Fast Track status to Debiopharm’s combination therapy of lunresertib (PKMYT1 inhibitor) and zedoresertib (WEE1 inhibitor) for platinum-resistant/refractory ovarian cancer with specific genomic alterations (CCNE1 amplification, FBXW7 or PPP2R1A mutations)


  • The designation follows Phase I results from the MYTHIC trial (NCT04855656), presented at AACR 2026 by Dr. Timothy Yap of MD Anderson
















FDA Grants Orphan Drug Status to Orion’s ODM-212 for Mesothelioma (Ref)


Orion Pharma’s investigational drug ODM-212 has been granted Orphan Drug Designation by the US FDA for malignant pleural mesothelioma (MPM), a rare and hard-to-treat cancer


  • Clinical Trial Context


  • Phase 2 clinical study (TEADES) is ongoing for the treatment of malignant pleural mesothelioma (MPM), epithelioid hemangioendothelioma (EHE) and other solid tumors with dysfunction in Hippo pathway


    • This is a Global study across US and European oncology centers


  • Enrolling patients who have progressed after standard treatments.


    • Primary endpoints: safety and tolerability.


    • Secondary endpoints: overall response rate, progression-free survival, and overall survival















FDA Grants Priority Review for PADCEV + Keytruda in Muscle-Invasive Bladder Cancer (Ref)


The FDA accepted a supplemental Biologics License Application (sBLA) for PADCEV™ (enfortumab vedotin) + Keytruda® (pembrolizumab) as perioperative treatment for muscle-invasive bladder cancer (MIBC), regardless of cisplatin eligibility. Target action date: August 17, 2026

  • Clinical Evidence (EV-304 Trial)


    • Showed 47% reduction in risk of recurrence/progression/death vs. standard gemcitabine + cisplatin


    • 35% reduction in risk of death


    • Pathological complete response rate: 55.8% vs 32.5% with chemotherapy arm


    • Safety profile consistent with prior experience, no new signals






bottom of page